Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other B-cell maturation antigen−targeting agents

MLA

Cohen, Adam D., et al. “Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Other B-Cell Maturation Antigen−targeting Agents.” Blood, no. Preprints, Jan. 2022. EBSCOhost, https://doi.org/10.1182/blood.2022015526.

APA

Cohen, A. D., Mateos, M.-V., Cohen, Y. C., Rodriguez-Otero, P., Paiva, B., van de Donk, N. W. C. J., Martin, T., Suvannasankha, A., De Braganca, K. C., Corsale, C., Schecter, J. M., Varsos, H., Deraedt, W., Wang, L., Vogel, M., Roccia, T., Xu, X., Mistry, P., Zudaire, E., … San-Miguel, J. (2022). Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other B-cell maturation antigen−targeting agents. Blood, Preprints. https://doi.org/10.1182/blood.2022015526

Chicago

Cohen, Adam D., María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W.C.J. van de Donk, Thomas Martin, et al. 2022. “Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Other B-Cell Maturation Antigen−targeting Agents.” Blood, no. Preprints (January). doi:10.1182/blood.2022015526.